Journal Report

Immunotherapy

Download PDF
Journal Information
Journal Title
Immunotherapy
Publisher
Taylor and Francis Ltd.
ISSN
1750-743X
E-ISSN
1750-7448
Database
SCOPUS
Domain
Health Sciences, Life Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Perioperative immunotherapy in muscle-invasive bladder cancer: a narrative review of neoadjuvant, adjuvant, and antibody-drug conjugate-based strategies
Caio Vinícius Suartz, Larissa Risério Fernandes, Camilly Nathalia Nunes Alves et al.
2026-11-12 Pages 1-14
DOI: 10.1080/1750743x.2026.2756124
Tumor-associated neutrophils in gastric cancer: dual roles with promising prognostic and therapeutic potential
Kamel A. Saleh, Moamin Mohammad Khdir, S. Renuka Jyothi et al.
2026-11-11 Pages 1-26
DOI: 10.1080/1750743x.2026.2759514
Tumor microenvironment modulation for immunotherapy in colorectal cancer: ‎integrating glycosylation into precision immuno-oncology
Abdulaziz Alfahed, Glowi Alasiri
2026-11-11 Pages 1-16
DOI: 10.1080/1750743x.2026.2759479
Next-generation dendritic cell and exosome vaccines in NSCLC: integrating personalized medicine, nanotechnology, AI, and microfluidics for enhanced immunotherapy
Mutaz Jamal Al-Khreisat, Alaa Khalaf Bediwi, Sarah Qutayba Badraldin et al.
2026-11-10 Pages 1-34
DOI: 10.1080/1750743x.2026.2758050
Co-existent autoimmune diseases in people with multiple sclerosis and a review on choice of immunotherapy
Aliakbar Netterwala, Surabhi Garg, Pritam Majumdar et al.
2026-11-9 Pages 1-10
DOI: 10.1080/1750743x.2026.2759490
Cost-effectiveness analysis of tarlatamab as second-line therapy for small-cell lung cancer after platinum-based chemotherapy
Zhengxiong Li, Jiaming Zhu, Kai Ma
2026-11-9 Pages 1-11
DOI: 10.1080/1750743x.2026.2758055
Bacterial ghosts: next-generation biological platforms for targeted cancer therapy and immunomodulation
Ghaleb Oriquat, Jasur Rizaev, Abdulqader Faris Abdulqader et al.
2026-11-8 Pages 1-14
DOI: 10.1080/1750743x.2026.2759526
Target engagement without clinical benefit: a systematic review, mechanism-concordant meta-analysis, and research agenda for Parkinson’s disease immunotherapy
Xingli Zhou, Seidu A. Richard, Zhigang Lan et al.
2026-11-6 Pages 1-20
DOI: 10.1080/1750743x.2026.2756119
Nanobodies as next-generation antigen recognition domains for CAR-based cellular immunotherapies in cancer
Amirhosein Maali, Shaghayegh Fazelian, Mahdieh Jafari et al.
2026-11-6 Pages 1-15
DOI: 10.1080/1750743x.2026.2755254
Fostamatinib in immune thrombocytopenia: real-world experience in European countries
Francesco Zaja, Maria Eva Mingot-Castellano, Guillaume Moulis
2026-11-5 Pages 1-9
DOI: 10.1080/1750743x.2026.2754679
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 12, 2026 22:03